Notizie AIOM – anno XV
FDA Accepts Filing for Binimetinib/Encorafenib Combo in BRAF+ Melanoma
September 13, 2017 - The FDA has accepted new drug applications (NDAs) supporting use of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The ...Leggi tutto
FDA approves new treatment for adults with relapsed follicular lymphoma
September 14, 2017 - The U.S. Food and Drug Administration today granted accelerated approval to copanlisib for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients with ...Leggi tutto
FDA approves first biosimilar for the treatment of cancer
September 14, 2017 - The U.S. Food and Drug Administration today approved bevacizumab-awwb as a biosimilar to bevacizumab for the treatment of multiple types of cancer. Bevacizumab-awwb is the first biosimilar approved in the U.S. for the treatment of cancer. “Bringing ...Leggi tutto
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore del pancreas è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...Leggi tutto
FDA Grants Cemiplimab Breakthrough Designation for CSCC
September 8, 2017 - The FDA has granted a breakthrough therapy designation to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, according to Regeneron Pharmaceuticals, ...Leggi tutto